A detailed history of Core Cap Advisors, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Core Cap Advisors, LLC holds 7,695 shares of GALT stock, worth $8,002. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,695
Holding current value
$8,002
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$2.04 - $2.86 $15,697 - $22,007
7,695 New
7,695 $21,000
Q1 2024

Aug 08, 2024

BUY
$1.6 - $2.44 $12,312 - $18,775
7,695 New
7,695 $18,000
Q4 2022

Feb 10, 2023

BUY
$1.03 - $1.66 $9,470 - $15,263
9,195 New
9,195 $10,000
Q2 2022

Aug 11, 2022

BUY
$1.19 - $1.74 $10,942 - $15,999
9,195 New
9,195 $12,000
Q1 2022

Apr 29, 2022

SELL
$1.61 - $2.31 $14,803 - $21,240
-9,195 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$2.07 - $3.8 $19,033 - $34,941
9,195 New
9,195 $19,000

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $61.8M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Core Cap Advisors, LLC Portfolio

Follow Core Cap Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Cap Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Core Cap Advisors, LLC with notifications on news.